iPR Pharmaceuticals Earns its 1st EPA’s ENERGY STAR® Certification for Superior Energy Efficiency

Outperforms similar U.S. Plants on measure of energy efficiency

iPR Pharmaceuticals, Inc., part of AstraZeneca, is proud to announce that it has earned the U.S. Environmental Protection Agency's (EPA) ENERGY STAR certification. This prestigious recognition confirms that the facility is among the top 25 percent of industrial sites nationwide in terms of energy efficiency and aligns with the stringent performance standards set by the EPA. This marks the first year iPR Pharmaceuticals, Inc. has achieved the ENERGY STAR certification, underscoring its commitment to ongoing energy savings.

Receiving the ENERGY STAR certification establishes iPR Pharmaceuticals, Inc. as a leader among pharmaceutical plants across the country regarding energy performance. The company has successfully enhanced its energy efficiency by strategically managing energy usage throughout the organization and implementing cost-effective upgrades to its facilities.

Sara M. Miranda Reyes, President and General Manager of iPR Pharmaceuticals, Inc. said: "We are pleased to accept the EPA's ENERGY STAR certification in recognition of our energy efficiency initiatives. This achievement reinforces our dedication to environmental stewardship while simultaneously reducing our energy costs."

Cindy Jacobs, Chief of the ENERGY STAR Commercial & Industrial Branch, said: "Improving the energy performance of our nation's industrial plants is essential to reducing greenhouse gas emissions. The EPA commends the commitment to energy efficiency demonstrated by ENERGY STAR certified facilities."

iPR Pharmaceuticals, Inc. achieved the ENERGY STAR certification through a series of strategic measures to improve energy efficiency and reduce emissions. The Company adopted advanced fuel technologies, employing Liquefied Natural Gas (LNG) and Renewable Liquefied Natural Gas (RLNG) in its boilers and Combined Heat and Power (CHP) plant. Additionally, iPR Pharmaceuticals integrated Photovoltaic (PV) solar systems complemented by battery banks and Variable Frequency Drive (VFD) compressors, which collectively contributed to a reduced CO2 footprint.

Other energy-efficient initiatives included upgrading the chiller plant and transitioning to LED lighting. The Company also established comprehensive daily tracking of energy consumption across its facilities, utilizing a Building Management System (BMS) for precise monitoring. Furthermore, iPR Pharmaceuticals, Inc. adopted LEAN methodologies to optimize efficiencies and minimize energy usage, exemplified by enhancements in manufacturing suites and the operational model of the chiller plant.

In line with AstraZeneca's Ambition Zero Carbon strategy, the Company is innovating to optimize the efficiency of their manufacturing processes and develop new sources of renewable energy. AstraZeneca's commitment to sustainable operations recognizes the interconnection between business growth and the needs of people, society and our planet.

AstraZeneca

AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialization of prescription medicines in Oncology, Rare Diseases and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Based in Cambridge, UK, AstraZeneca operates in over 125 countries, and its innovative medicines are used by millions of patients worldwide. For more information, please visit www.astrazeneca-us.com and follow us on social media @AstraZeneca.

Media Inquiries

Lisette Núñez	+1 787 406 3606